Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"
A M Evens, K R Carson, J Kolesar, et al.
British Journal of Haematology
|
June 10, 2000
Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1
S D Mundle, B Y Mativi, J D Cartlidge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
A M Evens, K R Carson, J Kolesar, et al.
Leukemia Research
|
August 11, 2000
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)
H D Preisler, P Venugopal, S A Gregory, et al.
Journal of Medicinal Chemistry
|
November 11, 1994
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors
D B Reitz, J J Li, M B Norton, et al.
Journal of Medicinal Chemistry
|
October 27, 1995
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents
J J Li, G D Anderson, E G Burton, et al.
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2000
Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4
H D Preisler, B Li, B L Yang, et al.
International Journal of Hematology
|
September 25, 1999
Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows
S D Mundle, B Y Mativi, K Bagai, et al.
Journal of Medicinal Chemistry
|
April 26, 1996
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents
J J Li, M B Norton, E J Reinhard, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"
A M Evens, K R Carson, J Kolesar, et al.
British Journal of Haematology
|
June 10, 2000
Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1
S D Mundle, B Y Mativi, J D Cartlidge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
A M Evens, K R Carson, J Kolesar, et al.
Leukemia Research
|
August 11, 2000
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)
H D Preisler, P Venugopal, S A Gregory, et al.
Journal of Medicinal Chemistry
|
November 11, 1994
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors
D B Reitz, J J Li, M B Norton, et al.
Journal of Medicinal Chemistry
|
October 27, 1995
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents
J J Li, G D Anderson, E G Burton, et al.
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2000
Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4
H D Preisler, B Li, B L Yang, et al.
International Journal of Hematology
|
September 25, 1999
Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows
S D Mundle, B Y Mativi, K Bagai, et al.
Journal of Medicinal Chemistry
|
April 26, 1996
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents
J J Li, M B Norton, E J Reinhard, et al.
Page
of 8